

Product Description

Moisture Retentive – For moderately exuding partial or full thickness wounds

DuoDERM® CGF™ (Controlled Gel Formulation) creates an occlusive moist wound environment which promotes healing of low to moderately exuding wounds^{1,2}. On contact with a moist wound surface, the unique hydrocolloid composition of DuoDERM® CGF™ dressing (Sodium Carboxymethylcellulose, gelatin, pectin and adhesive polymers) forms a cohesive gel which supports moist wound healing^{1,2}, aids autolytic debridement² and promotes granulation². Provides a bacterial and viral barrier^{*3}.

DuoDERM® CGF™ dressing keeps nerve endings moist, which helps provide relief from discomfort and pain^{4,5,6}. The dressing is easy to apply and remove, allowing non-traumatic removal of the dressing without damaging newly formed tissue^{6,7}.

With a wear time of up to 7 days DuoDERM® CGF™ dressing can contribute to cost-effective care⁷.

* in vitro

Application*

A clean, dry site is required. Select a dressing that extends at least 3cm beyond the wound edges. After removing the silicone backing paper, gently roll the dressing over the wound and mould into place for secure adhesion. DuoDERM® CGF™ dressing may be used as a secondary dressing, in combination with other appropriate dressings such as, but not limited to, AQUACEL®, DuoDERM® Hydroactive® Gel or KALTOSTAT® dressing.

To remove, press down on the skin and gently roll the dressing away.

*Please refer to pack insert for full instructions prior to use.

Specifications

Size	Dressings Per Box	Product Code
10 cm x 10 cm	5	187660
15 cm x 15 cm	5	187661
15 cm x 20 cm	5	187643
20 cm x 20 cm	5	187662
20 cm x 30 cm	5	187644

RPBS Codes

Size	Dressings Per Box	Product Code
10 cm x 10 cm	4897R	187660
20 cm x 20 cm	4920Y	187662

ARTG Number: 157332

References

1. Van Rijswijk L. Ingredient-based wound dressing classification: a paradigm that is passé and in need of replacement. *J Wound Care*. 2006;15 (1).
2. Pack Insert.
3. Bowler PG, Delargy H, Prince D, Fondberg L. The viral barrier properties of some occlusive dressings and their role in infection control. *Wounds*. 1993; 5(1): 1-8.
4. Burgess B. An investigation of hydrocolloids. *Professional Nurse*. 1993;8 (7) Supplement.
5. Day D. Managing sacral pressure ulcers with hydrocolloid dressings: Results of a controlled, clinical study. *Ostomy/Wound Management*. 1995;14 (2); 52-65.
6. Forshaw A. Hydrocolloid dressings in paediatric wound care. *J Wound Care*. 1993;2(4): 209-212.
7. Harding K, Cutting K, Price P. The cost-effectiveness of wound management protocols of care. *British Journal of Nursing*. 2000; 9 (19) Supplement.



Clinical Benefits

- Aids autolytic debridement²
- Supports moist wound healing environment¹
- Provides a bacterial and viral barrier^{*3}
- Easy to apply and remove^{5,6,7}
- More cost-effective than some traditional and modern dressings e.g. gauze

* in vitro

Indications

DuoDERM® CGF™ dressing is indicated for the management of low to moderately exuding wounds.

- Chronic wounds: pressure ulcers, leg ulcers
- Acute wounds: minor burns, skin donor sites, other surgical and traumatic wounds

Call your local ConvaTec Territory Manager or ConvaTec Support Centre for further information:

Australia: 1800 335 276 or New Zealand: 0800 441 763

www.convatec.com

ConvaTec (Australia) Pty Limited. ABN 70 131 232 570. Unipark Monash, Building 2, Ground Floor, 195 Wellington Road, Clayton VIC 3170 Australia. PO Box 63, Mulgrave, Vic 3170. Phone: (03) 9239 2700 Facsimile: (03) 9239 2743. ConvaTec (New Zealand) Limited. AK2135265 Level 4, 369 Queen Street, Auckland 1010 New Zealand. PO Box 62663, Kalmia Street, Auckland 1544 New Zealand. Phone: (09) 306 8833 Facsimile: (09) 306 8831.

®/™Indicates trademark of ConvaTec Inc. © 2009 ConvaTec Inc. AP-006692-AU. March 2009.

Our world is what we make of it™